Publications

Filter by year

Filter by type

Filter by year

Showing all years

Vitiligo - a disease: A position paper on stigmatization, life quality impairment and psychosocial comorbidity

M. Böhm, R. Sommer, U. Gieler, P. Staubach, A. Zink, C. Apfelbacher & E.M.J. Peters

Vitiligo is a common disorder characterized by the visible loss of skin pigmentation. Non-segmental vitiligo (NSV) is the major subtype. The disease is caused by autoimmune-mediated destruction of melanocytes. Vitiligo leads to stigmatization and a significant reduction in quality of life. We recommend optimizing care by incorporating the assessment of quality of life as a standard in routine care, in addition to monitoring disease activity.

PMID:
39167551
DOI:
https://doi.org/10.1111/ddg.15503

Impact of patient psoriasis on partner well-being in a real-world setting: 52-week interim data of the phase IV POSITIVE study

U. Mrowietz, R. Sommer, Z. Reguiai, S. Gerdes, E. Daudén, W. Weger, J.T. Maul, P. Laws, L. Naldi, P.D. Ghislain, E. de Jong, S. Mburu, V. Koscielny, E. Massana, I. Kasujee & M. Augustin

Poster presented at the 33rd EADV Congress, Amsterdam, the Netherlands

Need for individualized counseling regarding psoriasis systemic therapy in women of childbearing age: analysis of the PsoFem study at the University Medical Center Hamburg

B. Stephan, R. Sommer, M. Augustin, N. Ganjuur & N. da Silva-Burger

For patients with moderate-to-severe psoriasis and current childbearing/ pregnancy, the choice of therapy is limited.

The present study compared the disease burden and treatment choices in women of childbearing age (WoCBA) with and without a current wish for pregnancy.

Female patients aged 18 to 45 years, with moderate-to-severe psoriasis vulgaris, were consecutively recruited. The patients reported on sociodemographic/reproductive characteristics and quality of life impairments. The physicians assessed disease severity, comorbidities, and current treatment(s). Both patients’ and dermatologists’ perceptions of shared decision-making for the current systemic treatment were surveyed.

PMID:
39555230
DOI:
https://doi.org/10.1097/JW9.0000000000000187

High effectiveness of tildrakizumab regardless of baseline characteristics in patients with moderate-to-severe psoriasis: 52-week results from the POSITIVE study

U. Mrowietz, R. Sommer, Z. Reguiai, S. Gerdes, E. Daudén, W. Weger, J.T. Maul, P. Laws, L. Naldi, P.D. Ghislain, E. de Jong, S. Mburu, V. Koscielny, E. Massana, I. Kasujee & M. Augustin

Poster presented at the 33rd EADV Congress, Amsterdam, the Netherlands

Quality of Life in Infants and Toddlers with Dermatological Conditions – Validation of the German Version of the InToDermQoL Questionnaire

J. Traxler, N. da Silva-Burger, M. Augustin, H. Ott, S. Hoffmann, R. Fölster-Holst, M. Baumeister, P. Staubach & R. Sommer

Poster presentation presented at the 31st Annual Conference of ISOQOL, Cologne, Germany

Effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis located in special areas: 52-week results from the POSITIVE study

M. Augustin, R. Sommer, Z. Reguiai, S. Gerdes, E. Daudén, W. Weger, J.T. Maul, P. Laws, L. Naldi, P.D. Ghislain, E. de Jong, S. Mburu, V. Koscielny, E. Massana, I. Kasujee & U. Mrowietz

Poster presented at the 33rd EADV Congress, Amsterdam, the Netherlands

Psychosocial Burden in People with Atopic Dermatitis: Effects of a Substance-Free Basic Skincare in a Randomized Health Care Study

C.C. Braren-von Stülpnagel, M. Augustin, R. Sommer & L. Westphal

The aims of this study were to compare clinical and psychosocial parameters between patients with a different severity of atopic dermatitis and to analyse the effect of an omega-6-fatty-acid-skin therapy.

PMID:
38325354
DOI:
https://doi.org/10.1159/000536671

Patient-reported well-being using tildrakizumab in a real-world setting: 52-week interim data of the phase IV POSITIVE study

R. Sommer, M. Augustin, Z. Reguiai, S. Gerdes, E. Daudén, W. Weger, J.T. Maul, P. Laws, L. Naldi, P.D. Ghislain, E. de Jong, S. Mburu, V. Koscielny, E. Massana, I. Kasujee & U. Mrowietz

Poster presented at the 33rd EADV Congress, Amsterdam, the Netherlands

DEVISE – Entwicklung und Evaluation einer Online-Intervention zur Reduktion von Selbststigmatisierung bei Menschen mit sichtbaren chronischen Hauterkrankungen

J. Traxler, C.F.Z. Stuhlmann, N. da Silva-Burger, C. Stierle, M. Rudnik & R. Sommer

Oral presentation presented at the 23rd DKVF Conference, Potsdam, Germany

Socio-demographic diversity of the impact of dermatological diseases: Results from the patient-initiated Global Research on the Impact of Dermatological Disease (GRIDD) study

N. da Silva-Burger, R. Pattinson, N. Trialonis-Suthakharan, J. Austin, A. Fitzgerald, C. Bundy & M. Augustin

Oral presentation presented at the 31st Annual Conference of ISOQOL, Cologne, Germany

<< < 1 … 3 4 5 6 7 … 26 > >>